Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04296890 · ClinicalTrials.gov registry record · Phase 3
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
A Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT04296890 is a Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by ImmunoGen. The registered enrollment target is 106 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04296890, a Phase 3 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Participants will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight administered on Day 1 of every 3-week cycle.
Conditions Studied
Interventions
- DRUG Mirvetuximab Soravtansine
Study Locations (20)
California
- City of Hope Medical Center - Duarte
- California Cancer Associates (cCARE) - Fresno
- Stanford School of Medicine - Palo Alto
- California Pacific Medical Center Research Institute - San Francisco
Florida
- Sarasota Memorial Health Care System - Sarasota
- Florida Cancer Specialists Panhandle - Tallahassee
- University of South Florida - Tampa
- Florida Cancer Specialists Research - West Palm Beach
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arizona
- Arizona Oncology Associates - Phoenix
Colorado
- Rocky Mountain Cancer Centers - Littleton
Georgia
- Northside Hospital - Atlanta
Illinois
- Hinsdale Hospital - Hinsdale
Indiana
- St. Vincent Gynecologic Oncology - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04296890
The ClinicalTrials.gov registry entry for NCT04296890 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (58% lower). The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Mirvetuximab Soravtansine is the first listed.
NCT04296890 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04296890 about?
NCT04296890 is a clinical study titled "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression". This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). Particip...
What is the current status of trial NCT04296890?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2020-07-23. Estimated completion is 2022-11-16.
What conditions does trial NCT04296890 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT04296890?
The interventions under investigation include: Mirvetuximab Soravtansine (DRUG).
Who is sponsoring clinical trial NCT04296890?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04296890 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RECRUITING · Phase 3
-
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.